Arxis, Inc. Class A Common Stock (ARXS)vsThe Boeing Company (BA)
ARXS
Arxis, Inc. Class A Common Stock
$42.47
-3.61%
INDUSTRIALS · Cap: $17.14B
BA
The Boeing Company
$214.05
-3.41%
INDUSTRIALS · Cap: $164.48B
Smart Verdict
WallStSmart Research — data-driven comparison
The Boeing Company generates 5421% more annual revenue ($92.18B vs $1.67B). ARXS leads profitability with a 6.2% profit margin vs 2.5%. BA trades at a lower P/E of 80.6x. BA earns a higher WallStSmart Score of 48/100 (D+).
ARXS
Hold38
out of 100
Grade: F
BA
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARXS.
Margin of Safety
-76.6%
Fair Value
$121.18
Current Price
$214.05
$92.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 24.2%
Revenue surging 20.7% year-over-year
Every $100 of equity generates 40 in profit
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
6.2% margin — thin
Premium valuation, high expectations priced in
ROE of -1.6% — below average capital efficiency
2.5% margin — thin
Operating margin of 1.7%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ARXS
The strongest argument for ARXS centers on Operating Margin, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.
Bull Case : BA
The strongest argument for BA centers on Return on Equity, Market Cap. Revenue growth of 14.0% demonstrates continued momentum.
Bear Case : ARXS
The primary concerns for ARXS are EPS Growth, Profit Margin, P/E Ratio. A P/E of 2088.5x leaves little room for execution misses.
Bear Case : BA
The primary concerns for BA are Profit Margin, Operating Margin, PEG Ratio. A P/E of 80.6x leaves little room for execution misses. Debt-to-equity of 7.52 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARXS profiles as a growth stock while BA is a value play — different risk/reward profiles.
ARXS is growing revenue faster at 20.7% — sustainability is the question.
ARXS generates stronger free cash flow (25M), providing more financial flexibility.
Monitor AEROSPACE & DEFENSE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BA scores higher overall (48/100 vs 38/100) and 14.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arxis, Inc. Class A Common Stock
INDUSTRIALS · AEROSPACE & DEFENSE · USA
Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
The Boeing Company
INDUSTRIALS · AEROSPACE & DEFENSE · USA
The Boeing Company is an American multinational corporation that designs, manufactures, and sells airplanes, rotorcraft, rockets, satellites, telecommunications equipment, and missiles worldwide. The company also provides leasing and product support services.
Compare with Other AEROSPACE & DEFENSE Stocks
Want to dig deeper into these stocks?